Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea


You May Also Like

BeyondSpring Reports Third Quarter 2017 Operational and Financial Results

NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the ...

Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance

MADISON, Wis., May 11, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), ...